(Q34404280)

2 August 2017

title

SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia (English)

1 reference

2 August 2017

main subject

phase II clinical trial

0 references

0 references

1 reference

Frederick R. Appelbaum

11

object named as

Frederick R Appelbaum

1 reference

2 August 2017

10

Megan Othus

1 reference

2 August 2017

Anjali S Advani

1

1 reference

2 August 2017

Shannon McDonough

2

1 reference

2 August 2017

Steven Coutre

3

1 reference

2 August 2017

Brent Wood

4

1 reference

2 August 2017

Jerald Radich

5

1 reference

2 August 2017

Martha Mims

6

1 reference

2 August 2017

Margaret O'Donnell

7

1 reference

2 August 2017

Stephanie Elkins

8

1 reference

2 August 2017

Michael Becker

9

1 reference

2 August 2017

language of work or name

English

0 references

publication date

3 March 2014

1 reference

British Journal of Haematology

2 August 2017

published in

1 reference

2 August 2017

volume

165

1 reference

2 August 2017

issue

4

1 reference

2 August 2017

page(s)

504-509

1 reference

Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2

2 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4209396

Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4209396

Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4209396

Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4209396

Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4209396

High-dose chemotherapy in adult acute lymphoblastic leukemia

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4209396

Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study

6 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FBJH.12778

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FBJH.12778

Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24579885

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1111/BJH.12778

1 reference

2 August 2017

1 reference

2 August 2017

1 reference